Loading news...
In the most recent trading session, Oscar Health, Inc. (OSCR) closed at $13.3, indicating a -1.92% shift from the previous trading day.
These businesses will be long-term beneficiaries of new AI tools.
Oscar Health, Inc. (OSCR) closed at $13.23 in the latest trading session, marking a +1.77% move from the prior day.
Oscar Health, Inc. (NYSE: OSCR - Get Free Report) has been given a consensus recommendation of "Hold" by the ten analysts that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and two have assigned a buy recommendation to the company. The
The latest trading day saw Oscar Health, Inc. (OSCR) settling at $13, representing a -2.99% change from its previous close.
Citigroup Inc. reduced its stake in shares of Oscar Health, Inc. (NYSE: OSCR) by 23.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 122,248 shares of the company's stock after selling 36,619 shares during the quarter. Citigroup Inc.'s
Oscar Health ( NYSE:OSCR ) CEO Mark Bertolini has been making the same promise for four consecutive quarters: 2026 is the year the company turns profitable.
Oscar Health, Inc. (OSCR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OSCR broke out above the 50-day moving average, suggesting a short-term bullish trend.
Zacks.com users have recently been watching Oscar Health (OSCR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Oscar Health (OSCR) stock has declined by 21.7% in under a month, from $15.70 on January 26, 2026, to $12.30 currently. Should you consider purchasing this dip?
Raiffeisen Bank International AG acquired a new stake in shares of Oscar Health, Inc. (NYSE: OSCR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 61,881 shares of the company's stock, valued at approximately $1,171,000. Other hedge funds and other institutional investors
Health insurance stocks have been beaten down over the last year. Oscar Health is a disruptive health insurer set for a profit rebound this year.
Oscar Health (OSCR) leverages technology to drive operational efficiency and profitability in a challenging health insurance environment. Despite industry headwinds, OSCR's individual member retention remains strong, supporting optimism for revenue growth and market share gains. 2026 guidance targets $18.7–$19.0B revenue, 82.4–83.4% MLR, 15.8–16.3% SG&A, and $250–$450M operating earnings, implying significant valuation upside.
Oscar Health, Inc. reported 27% YoY revenue growth to $11.7bn in 2025 but remained unprofitable, missing analyst EPS and revenue estimates in Q4. OSCR expects >60% revenue growth in 2026 to $18.85bn at midpoint guidance, a return to profitability, and significant operating earnings improvement. Membership is projected to grow ~58% YoY to ~3 million, with AI-driven cost reductions and targeted product offerings supporting margin expansion.
2025 was a horrible year for the industry, but 2026 is a completely different story.
The healthcare company published its latest set of financial figures. It missed analyst estimates on both the top and bottom lines, but this was overshadowed by very bullish revenue guidance.
Oscar Health Inc. (NYSE: OSCR) on Tuesday reported fourth-quarter revenue of approximately $2.81 billion, compared to $2.39 billion a year ago, missing the consensus estimate of $3.12 billion.
Oscar Health, Inc. (OSCR) Q4 2025 Earnings Call Transcript
Although the revenue and EPS for Oscar Health (OSCR) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Oscar Health, Inc. (OSCR) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.62 per share a year ago.